|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
CTD_human |
Inhibitory H3 receptors on sympathetic nerves of the pithed rat: activation by endogenous histamine and operation in spontaneously hypertensive rats.
|
9050021 |
1997 |
|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
RGD |
Inhibitory H3 receptors on sympathetic nerves of the pithed rat: activation by endogenous histamine and operation in spontaneously hypertensive rats.
|
9050021 |
1997 |
|
Age-Related Memory Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Effect of endogenous histamine in the ventral hippocampus on fear memory deficits induced by scopolamine as evaluated by step-through avoidance response in rats.
|
16488453 |
2006 |
|
CNS disorder
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The successful cloning and functional expression of the histamine H(3) receptor in the late 1990 s has greatly facilitated our efforts to identify small molecule, non-imidazole based compounds to permit the evaluation of H(3) antagonists in models of CNS disorders.
|
17129577 |
2007 |
|
CNS disorder
|
0.020 |
Biomarker
|
group |
BEFREE |
Histamine H3 receptor antagonists are currently being evaluated for their potential use in a number of central nervous system disorders including Alzheimer's Disease (AD).
|
19222483 |
2009 |
|
Cognition Disorders
|
0.020 |
GeneticVariation
|
group |
BEFREE |
A partial agonist and a full antagonist of the histamine H3 receptor have been suggested to have therapeutic effects on cognitive deficits in psychiatric disorders.
|
28863002 |
2018 |
|
Cognition Disorders
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The histamine H<sub>3</sub> receptor (Hrh3), which is expressed in many brain areas involved in alcohol drinking and alcohol reward, can be targeted with a number of drugs developed initially for cognitive disorders and/or disorders related to sleep, wakefulness, and alertness.
|
30801695 |
2020 |
|
Sleep Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders.
|
30957954 |
2019 |
|
Sleep Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
|
15530639 |
2004 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Histamine H(3) receptor integrates peripheral inflammatory signals in the neurogenic control of immune responses and autoimmune disease susceptibility.
|
23894272 |
2013 |
|
Mental disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
A partial agonist and a full antagonist of the histamine H3 receptor have been suggested to have therapeutic effects on cognitive deficits in psychiatric disorders.
|
28863002 |
2018 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Recent studies have demonstrated that the expression of HRH3 is upregulated in several types of cancer.
|
31002350 |
2019 |
|
Psychotic Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
CHRM3 was co-expressed with three psychosis risk genes (GABAG2, CHRNA4, and HRH3) in the thalamus and other human brain tissues and mouse GABAergic neurons.
|
31740666 |
2019 |
|
Migraine Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
A280V polymorphism in the histamine H3 receptor as a risk factor for migraine.
|
21376262 |
2011 |
|
Parkinsonian Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The histamine H3 receptor antagonist thioperamide rescues circadian rhythm and memory function in experimental parkinsonism.
|
28398338 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Recent studies have demonstrated that the expression of HRH3 is upregulated in several types of cancer.
|
31002350 |
2019 |
|
Memory impairment
|
0.320 |
Biomarker
|
phenotype |
BEFREE |
Histamine H3 Receptor Antagonist Prevents Memory Deficits and Synaptic Plasticity Disruption Following Isoflurane Exposure.
|
28168839 |
2017 |
|
Memory impairment
|
0.320 |
Biomarker
|
phenotype |
BEFREE |
The Histamine H3 Receptor Antagonist E159 Reverses Memory Deficits Induced by Dizocilpine in Passive Avoidance and Novel Object Recognition Paradigm in Rats.
|
29075190 |
2017 |
|
Memory impairment
|
0.320 |
Biomarker
|
phenotype |
CTD_human |
Effect of endogenous histamine in the ventral hippocampus on fear memory deficits induced by scopolamine as evaluated by step-through avoidance response in rats.
|
16488453 |
2006 |
|
Hysterical amnesia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.
|
11125734 |
1999 |
|
Temporary Amnesia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.
|
11125734 |
1999 |
|
Dissociative Amnesia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.
|
11125734 |
1999 |
|
Global Amnesia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.
|
11125734 |
1999 |
|
Tactile Amnesia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.
|
11125734 |
1999 |
|
Amnestic State
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.
|
11125734 |
1999 |